ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 805

Takayasu Arteritis and Ulcerative Colitis –High Concurrence Ratio and Genetic Overlap

Chikashi Terao1, Takayoshi Matsumura2, Hajime Yoshifuji3, Yohei Kirino4, Yasuhiro Maejima5, Yoshikazu Nakaoka6, Meiko Takahashi1, Eisuke Amiya2, Natsuko Tamura5, Toshiki Nakajima3, Tomoki Origuchi7, Tetsuya Horita8, Mitsuru Matsukura2, Yuta Kochi2, Akiyoshi Ogimoto9, Motohisa Yamamoto10, Hiroki Takahashi11, Shingo Nakayamada12, Kazuyoshi Saito12, Yoko Wada13, Ichiei Narita13, Yasushi Kawaguchi14, Hisashi Yamanaka14, Koichiro Ohmura3, Tatsuya Atsumi8, Kazuo Tanemoto15, Tetsuro Miyata2, Masataka Kuwana16, Issei Komuro2, Yasuharu Tabara1, Atsuhisa Ueda17, Mitsuaki Isobe18, Tsuneyo Mimori3 and Fumihiko Matsuda1, 1Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 4Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Tokyo Medical and Dental University, Tokyo, Japan, 6Osaka University Graduate School of Medicine, Osaka, Japan, 7Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 9Ehime University Graduate School of Medicine, Ehime, Japan, 10Sapporo Medical University School of Medicine, Sapporo, Japan, 11First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, 12The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 13Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 14Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 15Kawasaki Medical School, Kurashiki, Japan, 16Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 17Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 18Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: complications and genetic architecture, Takayasu.s arteritis, Ulcerative Colitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose . Takayasu arteritis (TAK) is a systemic vasculitis affecting large arteries and large branches of the aorta. Ulcerative colitis (UC) is a prevalent autoimmune colitis. Since TAK and UC share HLA-B*52:01 and IL12B as genetic determinants, and concurrent cases of these two diseases have been reported, we hypothesized that UC is a common complication of TAK. Here, we performed an observational study to evaluate concurrence ratio of TAK and UC followed by genetic analysis of shared susceptibility genes between the two diseases.

Methods . A total of 470 consecutive patients with TAK from 14 Japanese institutions were registered. Concurrence ratio of TAK and UC were searched in each institution. We characterized patients with TAK and UC by analyzing clinical manifestations and genetic components. Genetic overlapping of TAK and UC was evaluated with use of UC susceptibility SNPs by comparing risk directions and effect sizes between susceptibility to the two diseases.

Results . We found that 29 patients out of 470 patients with TAK suffered from UC (6.2% (95%CI:4.2%-8.7%)). This ratio was much higher than expected based on prevalence of UC (0.11%). Patients with TAK and UC developed TAK at an earlier stage of life (p=0.0051) and showed significant enrichment of HLA-B*52:01 in comparison to patients without UC (p=1.9×10-5, OR:11.60, 95%CI:2.82-102.65).  The patients with the two diseases did not display higher frequency of aortic regurgitation (AR) or severer AR than patients without UC. While the TAK patients with UC displayed high risk allele frequency of rs6871626 in the IL12B region in comparison with patients without UC, the difference did not reach the significant level (88.0% vs 75.7%, p=0.22, OR:2.35 (0.68-12.53)). The 103 susceptibility SNPs to UC displayed common risk directions with TAK susceptibility (p=0.00074), while the 133 susceptibility SNPs to human height as a non-immunological reference did not show common risk directions with TAK susceptibility (p=0.13).

Conclusion . UC is a major complication of TAK. These two diseases share a significant proportion of their genetic background and HLA-B*52:01 may play a central role on the concurrence.


Disclosure:

C. Terao,
None;

T. Matsumura,
None;

H. Yoshifuji,
None;

Y. Kirino,
None;

Y. Maejima,
None;

Y. Nakaoka,
None;

M. Takahashi,
None;

E. Amiya,
None;

N. Tamura,
None;

T. Nakajima,
None;

T. Origuchi,
None;

T. Horita,
None;

M. Matsukura,
None;

Y. Kochi,
None;

A. Ogimoto,
None;

M. Yamamoto,
None;

H. Takahashi,
None;

S. Nakayamada,
None;

K. Saito,
None;

Y. Wada,
None;

I. Narita,
None;

Y. Kawaguchi,
None;

H. Yamanaka,
None;

K. Ohmura,
None;

T. Atsumi,
None;

K. Tanemoto,
None;

T. Miyata,
None;

M. Kuwana,
None;

I. Komuro,
None;

Y. Tabara,
None;

A. Ueda,
None;

M. Isobe,
None;

T. Mimori,
None;

F. Matsuda,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/takayasu-arteritis-and-ulcerative-colitis-high-concurrence-ratio-and-genetic-overlap/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology